Proteomic profiling of the substantia nigra demonstrates CNDP2 overexpression in Parkinson's disease
Authors:
- Mélanie CôteMCMélanie Côte
- Johannes Alexander LobrinusJLJohannes Alexander Lobrinus
- Neftali RodrigoNRNeftali Rodrigo
- Enikö KövariEKEnikö Kövari
- Denis F. HochstrasserDHDenis F. Hochstrasser
- Natacha TurckNTNatacha Turck
- Jean-Charles SanchezJSJean-Charles Sanchez
- Pierre R. BurkhardPBPierre R. Burkhard
- 1 August 2012
- journal article
- clinical trial
- Published by Elsevier in Journal of Proteomics
- Vol. 75 (15) , 4656-4667
Abstract
No abstract availableKeywords
Funding Information
- Memorial A. de Rothschild Foundation
- Edmond J. Safra Philanthropic Foundation
- Gustaaf Hamburger Foundation
- Ernst and Lucie Schmidheiny Foundation
- Swiss Parkinson
This publication has 37 references indexed in Scilit:
- Milestones in PD geneticsMovement Disorders, 2011
- Proteomic Identification of a Stress Protein, Mortalin/mthsp70/GRP75Molecular & Cellular Proteomics, 2006
- Staging of brain pathology related to sporadic Parkinson’s diseaseNeurobiology of Aging, 2003
- Proteasomal function is impaired in substantia nigra in Parkinson's diseaseNeuroscience Letters, 2001
- α-Synuclein in Lewy bodiesNature, 1997
- Neuropathology of Parkinsonʼs DiseaseJournal of Neuropathology & Experimental Neurology, 1996
- Parkinson's diseaseThe Lancet, 1990
- Mitochondrial Complex I Deficiency in Parkinson's DiseaseJournal of Neurochemistry, 1990
- Diffuse Lewy body disease: correlative neuropathology using anti-ubiquitin immunocytochemistry.Journal of Neurology, Neurosurgery & Psychiatry, 1989
- Chronic Parkinsonism in Humans Due to a Product of Meperidine-Analog SynthesisScience, 1983